# Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

> **NCT04190628** · PHASE1 · TERMINATED · sponsor: **ABM Therapeutics Corporation** · enrollment: 53 (actual)

## Conditions studied

- Advanced Solid Tumor
- BRAF V600 Mutation

## Interventions

- **DRUG:** ABM-1310
- **DRUG:** Cobimetinib

## Key facts

- **NCT ID:** NCT04190628
- **Lead sponsor:** ABM Therapeutics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-16
- **Primary completion:** 2024-04-05
- **Final completion:** 2024-04-05
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** Not related to safety concerns or lack of efficacy
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04190628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04190628, "Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04190628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*